Evotec SE (NASDAQ: EVO) Stock Competitors & Peer Comparison
See EVO's competitors and their performance on the NASDAQ and across the wider stock market.
Peer Comparison Table: Drug Manufacturers - Specialty & Generic Industry
Detailed financial metrics including price, market cap, P/E ratio, and more for EVO and its NASDAQ peers.
| Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
|---|---|---|---|---|---|---|
| EVO | $1.59 | +2.25% | 564.8M | -2.25 | -$0.71 | N/A |
| TAK | $18.90 | +0.21% | 60.2B | 13.59 | $1.39 | +3.34% |
| TEVA | $38.88 | -0.79% | 45.3B | 13.27 | $2.93 | N/A |
| HLN | $9.17 | -0.97% | 40.4B | 18.78 | $0.49 | +2.16% |
| ZTS | $71.43 | +0.53% | 29.9B | 10.85 | $6.58 | +2.93% |
| VTRS | $18.27 | +2.47% | 21.3B | 7.25 | $2.52 | +2.62% |
| ITCI | $131.87 | +0.00% | 14B | -180.64 | -$0.73 | N/A |
| CTLT | $63.48 | +0.00% | 11.5B | -27.84 | -$2.28 | N/A |
| ELAN | $22.45 | +0.63% | 11.2B | 21.17 | $1.06 | N/A |
| RDY | $12.51 | +2.12% | 10.4B | 20.52 | $0.61 | +0.66% |
Stock Comparison
Takeda Pharmaceutical Company Limited (NYSE: TAK)
EVO vs TAK Comparison September 2026
Evotec SE (NASDAQ: EVO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EVO stands at 564.8M. In comparison, TAK has a market cap of 60.2B. Regarding current trading prices, EVO is priced at $1.59 on the NASDAQ, while TAK trades at $18.90.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EVO currently has a P/E ratio of -2.25, whereas TAK's P/E ratio is 13.59. In terms of profitability, EVO's ROE is -0.27%, compared to TAK's ROE of +0.02%. Regarding short-term risk, EVO is more volatile compared to TAK. This indicates higher risk in terms of short-term price fluctuations for EVO.Check TAK's competition here
Teva Pharmaceutical Industries Limited (NYSE: TEVA)
EVO vs TEVA Comparison September 2026
Evotec SE (NASDAQ: EVO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EVO stands at 564.8M. In comparison, TEVA has a market cap of 45.3B. Regarding current trading prices, EVO is priced at $1.59 on the NASDAQ, while TEVA trades at $38.88.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EVO currently has a P/E ratio of -2.25, whereas TEVA's P/E ratio is 13.27. In terms of profitability, EVO's ROE is -0.27%, compared to TEVA's ROE of +0.09%. Regarding short-term risk, EVO is less volatile compared to TEVA. This indicates lower risk in terms of short-term price fluctuations for EVO.Check TEVA's competition here
Haleon plc (NYSE: HLN)
EVO vs HLN Comparison September 2026
Evotec SE (NASDAQ: EVO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EVO stands at 564.8M. In comparison, HLN has a market cap of 40.4B. Regarding current trading prices, EVO is priced at $1.59 on the NASDAQ, while HLN trades at $9.17.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EVO currently has a P/E ratio of -2.25, whereas HLN's P/E ratio is 18.78. In terms of profitability, EVO's ROE is -0.27%, compared to HLN's ROE of +0.17%. Regarding short-term risk, EVO is more volatile compared to HLN. This indicates higher risk in terms of short-term price fluctuations for EVO.Check HLN's competition here
Zoetis Inc. (NYSE: ZTS)
EVO vs ZTS Comparison September 2026
Evotec SE (NASDAQ: EVO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EVO stands at 564.8M. In comparison, ZTS has a market cap of 29.9B. Regarding current trading prices, EVO is priced at $1.59 on the NASDAQ, while ZTS trades at $71.43.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EVO currently has a P/E ratio of -2.25, whereas ZTS's P/E ratio is 10.85. In terms of profitability, EVO's ROE is -0.27%, compared to ZTS's ROE of +0.69%. Regarding short-term risk, EVO is less volatile compared to ZTS. This indicates lower risk in terms of short-term price fluctuations for EVO.Check ZTS's competition here
Viatris Inc. (NASDAQ: VTRS)
EVO vs VTRS Comparison September 2026
Evotec SE (NASDAQ: EVO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EVO stands at 564.8M. In comparison, VTRS has a market cap of 21.3B. Regarding current trading prices, EVO is priced at $1.59 on the NASDAQ, while VTRS trades at $18.27.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EVO currently has a P/E ratio of -2.25, whereas VTRS's P/E ratio is 7.25. In terms of profitability, EVO's ROE is -0.27%, compared to VTRS's ROE of -0.03%. Regarding short-term risk, EVO is less volatile compared to VTRS. This indicates lower risk in terms of short-term price fluctuations for EVO.Check VTRS's competition here
Intra-Cellular Therapies, Inc. (NASDAQ: ITCI)
EVO vs ITCI Comparison September 2026
Evotec SE (NASDAQ: EVO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EVO stands at 564.8M. In comparison, ITCI has a market cap of 14B. Regarding current trading prices, EVO is priced at $1.59 on the NASDAQ, while ITCI trades at $131.87.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EVO currently has a P/E ratio of -2.25, whereas ITCI's P/E ratio is -180.64. In terms of profitability, EVO's ROE is -0.27%, compared to ITCI's ROE of -0.09%. Regarding short-term risk, EVO is more volatile compared to ITCI. This indicates higher risk in terms of short-term price fluctuations for EVO.Check ITCI's competition here
Catalent, Inc. (NYSE: CTLT)
EVO vs CTLT Comparison September 2026
Evotec SE (NASDAQ: EVO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EVO stands at 564.8M. In comparison, CTLT has a market cap of 11.5B. Regarding current trading prices, EVO is priced at $1.59 on the NASDAQ, while CTLT trades at $63.48.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EVO currently has a P/E ratio of -2.25, whereas CTLT's P/E ratio is -27.84. In terms of profitability, EVO's ROE is -0.27%, compared to CTLT's ROE of -0.25%. Regarding short-term risk, EVO is more volatile compared to CTLT. This indicates higher risk in terms of short-term price fluctuations for EVO.Check CTLT's competition here
Elanco Animal Health Incorporated (NYSE: ELAN)
EVO vs ELAN Comparison September 2026
Evotec SE (NASDAQ: EVO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EVO stands at 564.8M. In comparison, ELAN has a market cap of 11.2B. Regarding current trading prices, EVO is priced at $1.59 on the NASDAQ, while ELAN trades at $22.45.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EVO currently has a P/E ratio of -2.25, whereas ELAN's P/E ratio is 21.17. In terms of profitability, EVO's ROE is -0.27%, compared to ELAN's ROE of -0.03%. Regarding short-term risk, EVO is less volatile compared to ELAN. This indicates lower risk in terms of short-term price fluctuations for EVO.Check ELAN's competition here
Dr. Reddy's Laboratories Limited (NYSE: RDY)
EVO vs RDY Comparison September 2026
Evotec SE (NASDAQ: EVO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EVO stands at 564.8M. In comparison, RDY has a market cap of 10.4B. Regarding current trading prices, EVO is priced at $1.59 on the NASDAQ, while RDY trades at $12.51.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EVO currently has a P/E ratio of -2.25, whereas RDY's P/E ratio is 20.52. In terms of profitability, EVO's ROE is -0.27%, compared to RDY's ROE of +0.09%. Regarding short-term risk, EVO is less volatile compared to RDY. This indicates lower risk in terms of short-term price fluctuations for EVO.Check RDY's competition here
Alkermes plc (NASDAQ: ALKS)
EVO vs ALKS Comparison September 2026
Evotec SE (NASDAQ: EVO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EVO stands at 564.8M. In comparison, ALKS has a market cap of 6.7B. Regarding current trading prices, EVO is priced at $1.59 on the NASDAQ, while ALKS trades at $40.15.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EVO currently has a P/E ratio of -2.25, whereas ALKS's P/E ratio is 42.26. In terms of profitability, EVO's ROE is -0.27%, compared to ALKS's ROE of +0.04%. Regarding short-term risk, EVO is less volatile compared to ALKS. This indicates lower risk in terms of short-term price fluctuations for EVO.Check ALKS's competition here
Amneal Pharmaceuticals, Inc. (NASDAQ: AMRX)
EVO vs AMRX Comparison September 2026
Evotec SE (NASDAQ: EVO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EVO stands at 564.8M. In comparison, AMRX has a market cap of 6.5B. Regarding current trading prices, EVO is priced at $1.59 on the NASDAQ, while AMRX trades at $20.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EVO currently has a P/E ratio of -2.25, whereas AMRX's P/E ratio is 22.78. In terms of profitability, EVO's ROE is -0.27%, compared to AMRX's ROE of -3.27%. Regarding short-term risk, EVO is less volatile compared to AMRX. This indicates lower risk in terms of short-term price fluctuations for EVO.Check AMRX's competition here
Lantheus Holdings, Inc. (NASDAQ: LNTH)
EVO vs LNTH Comparison September 2026
Evotec SE (NASDAQ: EVO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EVO stands at 564.8M. In comparison, LNTH has a market cap of 6.5B. Regarding current trading prices, EVO is priced at $1.59 on the NASDAQ, while LNTH trades at $99.74.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EVO currently has a P/E ratio of -2.25, whereas LNTH's P/E ratio is 16.76. In terms of profitability, EVO's ROE is -0.27%, compared to LNTH's ROE of +0.23%. Regarding short-term risk, EVO is more volatile compared to LNTH. This indicates higher risk in terms of short-term price fluctuations for EVO.Check LNTH's competition here
Indivior Pharmaceuticals Inc (NASDAQ: INDV)
EVO vs INDV Comparison September 2026
Evotec SE (NASDAQ: EVO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EVO stands at 564.8M. In comparison, INDV has a market cap of 4.6B. Regarding current trading prices, EVO is priced at $1.59 on the NASDAQ, while INDV trades at $36.88.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EVO currently has a P/E ratio of -2.25, whereas INDV's P/E ratio is 10.10. In terms of profitability, EVO's ROE is -0.27%, compared to INDV's ROE of -2.16%. Regarding short-term risk, EVO is less volatile compared to INDV. This indicates lower risk in terms of short-term price fluctuations for EVO.Check INDV's competition here
Alvotech (NASDAQ: ALVOW)
EVO vs ALVOW Comparison September 2026
Evotec SE (NASDAQ: EVO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EVO stands at 564.8M. In comparison, ALVOW has a market cap of 3.5B. Regarding current trading prices, EVO is priced at $1.59 on the NASDAQ, while ALVOW trades at $0.38.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EVO currently has a P/E ratio of -2.25, whereas ALVOW's P/E ratio is 55.38. In terms of profitability, EVO's ROE is -0.27%, compared to ALVOW's ROE of +0.77%. Regarding short-term risk, EVO is more volatile compared to ALVOW. This indicates higher risk in terms of short-term price fluctuations for EVO.Check ALVOW's competition here
Regencell Bioscience Holdings Limited (NASDAQ: RGC)
EVO vs RGC Comparison September 2026
Evotec SE (NASDAQ: EVO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EVO stands at 564.8M. In comparison, RGC has a market cap of 3.1B. Regarding current trading prices, EVO is priced at $1.59 on the NASDAQ, while RGC trades at $6.20.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EVO currently has a P/E ratio of -2.25, whereas RGC's P/E ratio is -436.62. In terms of profitability, EVO's ROE is -0.27%, compared to RGC's ROE of -2.32%. Regarding short-term risk, EVO is less volatile compared to RGC. This indicates lower risk in terms of short-term price fluctuations for EVO.Check RGC's competition here
Supernus Pharmaceuticals, Inc. (NASDAQ: SUPN)
EVO vs SUPN Comparison September 2026
Evotec SE (NASDAQ: EVO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EVO stands at 564.8M. In comparison, SUPN has a market cap of 2.6B. Regarding current trading prices, EVO is priced at $1.59 on the NASDAQ, while SUPN trades at $44.60.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EVO currently has a P/E ratio of -2.25, whereas SUPN's P/E ratio is 14.58. In terms of profitability, EVO's ROE is -0.27%, compared to SUPN's ROE of -0.10%. Regarding short-term risk, EVO is less volatile compared to SUPN. This indicates lower risk in terms of short-term price fluctuations for EVO.Check SUPN's competition here
HUTCHMED (China) Limited (NASDAQ: HCM)
EVO vs HCM Comparison September 2026
Evotec SE (NASDAQ: EVO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EVO stands at 564.8M. In comparison, HCM has a market cap of 2.5B. Regarding current trading prices, EVO is priced at $1.59 on the NASDAQ, while HCM trades at $14.13.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EVO currently has a P/E ratio of -2.25, whereas HCM's P/E ratio is 5.30. In terms of profitability, EVO's ROE is -0.27%, compared to HCM's ROE of +0.01%. Regarding short-term risk, EVO is less volatile compared to HCM. This indicates lower risk in terms of short-term price fluctuations for EVO.Check HCM's competition here
Deciphera Pharmaceuticals, Inc. (NASDAQ: DCPH)
EVO vs DCPH Comparison September 2026
Evotec SE (NASDAQ: EVO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EVO stands at 564.8M. In comparison, DCPH has a market cap of 2.2B. Regarding current trading prices, EVO is priced at $1.59 on the NASDAQ, while DCPH trades at $25.59.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EVO currently has a P/E ratio of -2.25, whereas DCPH's P/E ratio is -11.58. In terms of profitability, EVO's ROE is -0.27%, compared to DCPH's ROE of -0.56%. Regarding short-term risk, EVO is more volatile compared to DCPH. This indicates higher risk in terms of short-term price fluctuations for EVO.Check DCPH's competition here
Bausch Health Companies Inc. (NYSE: BHC)
EVO vs BHC Comparison September 2026
Evotec SE (NASDAQ: EVO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EVO stands at 564.8M. In comparison, BHC has a market cap of 2.2B. Regarding current trading prices, EVO is priced at $1.59 on the NASDAQ, while BHC trades at $5.77.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EVO currently has a P/E ratio of -2.25, whereas BHC's P/E ratio is 1.47. In terms of profitability, EVO's ROE is -0.27%, compared to BHC's ROE of +0.89%. Regarding short-term risk, EVO is less volatile compared to BHC. This indicates lower risk in terms of short-term price fluctuations for EVO.Check BHC's competition here
Avadel Pharmaceuticals plc (NASDAQ: AVDL)
EVO vs AVDL Comparison September 2026
Evotec SE (NASDAQ: EVO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EVO stands at 564.8M. In comparison, AVDL has a market cap of 2.1B. Regarding current trading prices, EVO is priced at $1.59 on the NASDAQ, while AVDL trades at $21.64.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EVO currently has a P/E ratio of -2.25, whereas AVDL's P/E ratio is -1082.00. In terms of profitability, EVO's ROE is -0.27%, compared to AVDL's ROE of +0.05%. Regarding short-term risk, EVO is more volatile compared to AVDL. This indicates higher risk in terms of short-term price fluctuations for EVO.Check AVDL's competition here
Trulieve Cannabis Corp. (NYSE: TRLV)
EVO vs TRLV Comparison September 2026
Evotec SE (NASDAQ: EVO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EVO stands at 564.8M. In comparison, TRLV has a market cap of 2.1B. Regarding current trading prices, EVO is priced at $1.59 on the NASDAQ, while TRLV trades at $12.34.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EVO currently has a P/E ratio of -2.25, whereas TRLV's P/E ratio is -5.02. In terms of profitability, EVO's ROE is -0.27%, compared to TRLV's ROE of -0.44%. Regarding short-term risk, EVO is less volatile compared to TRLV. This indicates lower risk in terms of short-term price fluctuations for EVO.Check TRLV's competition here
Perrigo Company plc (NYSE: PRGO)
EVO vs PRGO Comparison September 2026
Evotec SE (NASDAQ: EVO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EVO stands at 564.8M. In comparison, PRGO has a market cap of 2.1B. Regarding current trading prices, EVO is priced at $1.59 on the NASDAQ, while PRGO trades at $15.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EVO currently has a P/E ratio of -2.25, whereas PRGO's P/E ratio is 6.03. In terms of profitability, EVO's ROE is -0.27%, compared to PRGO's ROE of -0.56%. Regarding short-term risk, EVO is less volatile compared to PRGO. This indicates lower risk in terms of short-term price fluctuations for EVO.Check PRGO's competition here
Alvotech (NASDAQ: ALVO)
EVO vs ALVO Comparison September 2026
Evotec SE (NASDAQ: EVO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EVO stands at 564.8M. In comparison, ALVO has a market cap of 2.1B. Regarding current trading prices, EVO is priced at $1.59 on the NASDAQ, while ALVO trades at $6.15.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EVO currently has a P/E ratio of -2.25, whereas ALVO's P/E ratio is -10.42. In terms of profitability, EVO's ROE is -0.27%, compared to ALVO's ROE of +0.77%. Regarding short-term risk, EVO is less volatile compared to ALVO. This indicates lower risk in terms of short-term price fluctuations for EVO.Check ALVO's competition here
Embecta Corp. (NASDAQ: EMBCV)
EVO vs EMBCV Comparison September 2026
Evotec SE (NASDAQ: EVO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EVO stands at 564.8M. In comparison, EMBCV has a market cap of 1.9B. Regarding current trading prices, EVO is priced at $1.59 on the NASDAQ, while EMBCV trades at $33.33.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EVO currently has a P/E ratio of -2.25, whereas EMBCV's P/E ratio is N/A. In terms of profitability, EVO's ROE is -0.27%, compared to EMBCV's ROE of -0.19%. Regarding short-term risk, EVO is less volatile compared to EMBCV. This indicates lower risk in terms of short-term price fluctuations for EVO.Check EMBCV's competition here
Dynavax Technologies Corporation (NASDAQ: DVAX)
EVO vs DVAX Comparison September 2026
Evotec SE (NASDAQ: EVO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EVO stands at 564.8M. In comparison, DVAX has a market cap of 1.8B. Regarding current trading prices, EVO is priced at $1.59 on the NASDAQ, while DVAX trades at $15.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EVO currently has a P/E ratio of -2.25, whereas DVAX's P/E ratio is -41.89. In terms of profitability, EVO's ROE is -0.27%, compared to DVAX's ROE of -0.10%. Regarding short-term risk, EVO is more volatile compared to DVAX. This indicates higher risk in terms of short-term price fluctuations for EVO.Check DVAX's competition here
ANI Pharmaceuticals, Inc. (NASDAQ: ANIP)
EVO vs ANIP Comparison September 2026
Evotec SE (NASDAQ: EVO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EVO stands at 564.8M. In comparison, ANIP has a market cap of 1.7B. Regarding current trading prices, EVO is priced at $1.59 on the NASDAQ, while ANIP trades at $74.83.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EVO currently has a P/E ratio of -2.25, whereas ANIP's P/E ratio is 9.10. In terms of profitability, EVO's ROE is -0.27%, compared to ANIP's ROE of +0.19%. Regarding short-term risk, EVO is less volatile compared to ANIP. This indicates lower risk in terms of short-term price fluctuations for EVO.Check ANIP's competition here
Eton Pharmaceuticals, Inc. (NASDAQ: ETON)
EVO vs ETON Comparison September 2026
Evotec SE (NASDAQ: EVO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EVO stands at 564.8M. In comparison, ETON has a market cap of 1.6B. Regarding current trading prices, EVO is priced at $1.59 on the NASDAQ, while ETON trades at $59.18.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EVO currently has a P/E ratio of -2.25, whereas ETON's P/E ratio is 155.74. In terms of profitability, EVO's ROE is -0.27%, compared to ETON's ROE of +0.40%. Regarding short-term risk, EVO is less volatile compared to ETON. This indicates lower risk in terms of short-term price fluctuations for EVO.Check ETON's competition here
Taro Pharmaceutical Industries Ltd. (NYSE: TARO)
EVO vs TARO Comparison September 2026
Evotec SE (NASDAQ: EVO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EVO stands at 564.8M. In comparison, TARO has a market cap of 1.6B. Regarding current trading prices, EVO is priced at $1.59 on the NASDAQ, while TARO trades at $42.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EVO currently has a P/E ratio of -2.25, whereas TARO's P/E ratio is 30.05. In terms of profitability, EVO's ROE is -0.27%, compared to TARO's ROE of +0.03%. Regarding short-term risk, EVO is more volatile compared to TARO. This indicates higher risk in terms of short-term price fluctuations for EVO.Check TARO's competition here
Phibro Animal Health Corporation (NASDAQ: PAHC)
EVO vs PAHC Comparison September 2026
Evotec SE (NASDAQ: EVO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EVO stands at 564.8M. In comparison, PAHC has a market cap of 1.4B. Regarding current trading prices, EVO is priced at $1.59 on the NASDAQ, while PAHC trades at $35.70.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EVO currently has a P/E ratio of -2.25, whereas PAHC's P/E ratio is 12.18. In terms of profitability, EVO's ROE is -0.27%, compared to PAHC's ROE of +0.29%. Regarding short-term risk, EVO is less volatile compared to PAHC. This indicates lower risk in terms of short-term price fluctuations for EVO.Check PAHC's competition here
Cronos Group Inc. (NASDAQ: CRON)
EVO vs CRON Comparison September 2026
Evotec SE (NASDAQ: EVO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EVO stands at 564.8M. In comparison, CRON has a market cap of 1.3B. Regarding current trading prices, EVO is priced at $1.59 on the NASDAQ, while CRON trades at $3.41.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EVO currently has a P/E ratio of -2.25, whereas CRON's P/E ratio is 17.46. In terms of profitability, EVO's ROE is -0.27%, compared to CRON's ROE of +0.06%. Regarding short-term risk, EVO is less volatile compared to CRON. This indicates lower risk in terms of short-term price fluctuations for EVO.Check CRON's competition here
Amphastar Pharmaceuticals, Inc. (NASDAQ: AMPH)
EVO vs AMPH Comparison September 2026
Evotec SE (NASDAQ: EVO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EVO stands at 564.8M. In comparison, AMPH has a market cap of 1.2B. Regarding current trading prices, EVO is priced at $1.59 on the NASDAQ, while AMPH trades at $27.39.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EVO currently has a P/E ratio of -2.25, whereas AMPH's P/E ratio is 9.35. In terms of profitability, EVO's ROE is -0.27%, compared to AMPH's ROE of +0.10%. Regarding short-term risk, EVO is less volatile compared to AMPH. This indicates lower risk in terms of short-term price fluctuations for EVO.Check AMPH's competition here
Harrow Health, Inc. (NASDAQ: HROW)
EVO vs HROW Comparison September 2026
Evotec SE (NASDAQ: EVO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EVO stands at 564.8M. In comparison, HROW has a market cap of 1.2B. Regarding current trading prices, EVO is priced at $1.59 on the NASDAQ, while HROW trades at $31.60.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EVO currently has a P/E ratio of -2.25, whereas HROW's P/E ratio is -31.92. In terms of profitability, EVO's ROE is -0.27%, compared to HROW's ROE of -1.04%. Regarding short-term risk, EVO is less volatile compared to HROW. This indicates lower risk in terms of short-term price fluctuations for EVO.Check HROW's competition here
Pacira BioSciences, Inc. (NASDAQ: PCRX)
EVO vs PCRX Comparison September 2026
Evotec SE (NASDAQ: EVO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EVO stands at 564.8M. In comparison, PCRX has a market cap of 998.7M. Regarding current trading prices, EVO is priced at $1.59 on the NASDAQ, while PCRX trades at $25.39.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EVO currently has a P/E ratio of -2.25, whereas PCRX's P/E ratio is 9.77. In terms of profitability, EVO's ROE is -0.27%, compared to PCRX's ROE of +0.02%. Regarding short-term risk, EVO is less volatile compared to PCRX. This indicates lower risk in terms of short-term price fluctuations for EVO.Check PCRX's competition here
PetIQ, Inc. (NASDAQ: PETQ)
EVO vs PETQ Comparison September 2026
Evotec SE (NASDAQ: EVO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EVO stands at 564.8M. In comparison, PETQ has a market cap of 919.2M. Regarding current trading prices, EVO is priced at $1.59 on the NASDAQ, while PETQ trades at $30.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EVO currently has a P/E ratio of -2.25, whereas PETQ's P/E ratio is 83.73. In terms of profitability, EVO's ROE is -0.27%, compared to PETQ's ROE of +0.01%. Regarding short-term risk, EVO is more volatile compared to PETQ. This indicates higher risk in terms of short-term price fluctuations for EVO.Check PETQ's competition here
Collegium Pharmaceutical, Inc. (NASDAQ: COLL)
EVO vs COLL Comparison September 2026
Evotec SE (NASDAQ: EVO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EVO stands at 564.8M. In comparison, COLL has a market cap of 734M. Regarding current trading prices, EVO is priced at $1.59 on the NASDAQ, while COLL trades at $22.63.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EVO currently has a P/E ratio of -2.25, whereas COLL's P/E ratio is 2.84. In terms of profitability, EVO's ROE is -0.27%, compared to COLL's ROE of +0.16%. Regarding short-term risk, EVO is less volatile compared to COLL. This indicates lower risk in terms of short-term price fluctuations for EVO.Check COLL's competition here
Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD)
EVO vs IRWD Comparison September 2026
Evotec SE (NASDAQ: EVO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EVO stands at 564.8M. In comparison, IRWD has a market cap of 678.2M. Regarding current trading prices, EVO is priced at $1.59 on the NASDAQ, while IRWD trades at $4.12.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EVO currently has a P/E ratio of -2.25, whereas IRWD's P/E ratio is 5.28. In terms of profitability, EVO's ROE is -0.27%, compared to IRWD's ROE of -0.57%. Regarding short-term risk, EVO is less volatile compared to IRWD. This indicates lower risk in terms of short-term price fluctuations for EVO.Check IRWD's competition here
Aquestive Therapeutics, Inc. (NASDAQ: AQST)
EVO vs AQST Comparison September 2026
Evotec SE (NASDAQ: EVO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EVO stands at 564.8M. In comparison, AQST has a market cap of 596M. Regarding current trading prices, EVO is priced at $1.59 on the NASDAQ, while AQST trades at $4.75.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EVO currently has a P/E ratio of -2.25, whereas AQST's P/E ratio is -7.31. In terms of profitability, EVO's ROE is -0.27%, compared to AQST's ROE of +2.44%. Regarding short-term risk, EVO is less volatile compared to AQST. This indicates lower risk in terms of short-term price fluctuations for EVO.Check AQST's competition here
BioDelivery Sciences International, Inc. (NASDAQ: BDSI)
EVO vs BDSI Comparison September 2026
Evotec SE (NASDAQ: EVO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EVO stands at 564.8M. In comparison, BDSI has a market cap of 577.1M. Regarding current trading prices, EVO is priced at $1.59 on the NASDAQ, while BDSI trades at $5.59.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EVO currently has a P/E ratio of -2.25, whereas BDSI's P/E ratio is 6.82. In terms of profitability, EVO's ROE is -0.27%, compared to BDSI's ROE of +0.57%. Regarding short-term risk, EVO is more volatile compared to BDSI. This indicates higher risk in terms of short-term price fluctuations for EVO.Check BDSI's competition here
Glass House Brands Inc (NYSE: GLAS)
EVO vs GLAS Comparison September 2026
Evotec SE (NASDAQ: EVO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EVO stands at 564.8M. In comparison, GLAS has a market cap of 529.2M. Regarding current trading prices, EVO is priced at $1.59 on the NASDAQ, while GLAS trades at $6.85.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EVO currently has a P/E ratio of -2.25, whereas GLAS's P/E ratio is -12.22. In terms of profitability, EVO's ROE is -0.27%, compared to GLAS's ROE of -0.51%. Regarding short-term risk, EVO is less volatile compared to GLAS. This indicates lower risk in terms of short-term price fluctuations for EVO.Check GLAS's competition here
Evolus, Inc. (NASDAQ: EOLS)
EVO vs EOLS Comparison September 2026
Evotec SE (NASDAQ: EVO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EVO stands at 564.8M. In comparison, EOLS has a market cap of 524.2M. Regarding current trading prices, EVO is priced at $1.59 on the NASDAQ, while EOLS trades at $7.96.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EVO currently has a P/E ratio of -2.25, whereas EOLS's P/E ratio is -25.21. In terms of profitability, EVO's ROE is -0.27%, compared to EOLS's ROE of +1.23%. Regarding short-term risk, EVO is less volatile compared to EOLS. This indicates lower risk in terms of short-term price fluctuations for EVO.Check EOLS's competition here
Kamada Ltd. (NASDAQ: KMDA)
EVO vs KMDA Comparison September 2026
Evotec SE (NASDAQ: EVO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EVO stands at 564.8M. In comparison, KMDA has a market cap of 497.3M. Regarding current trading prices, EVO is priced at $1.59 on the NASDAQ, while KMDA trades at $8.62.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EVO currently has a P/E ratio of -2.25, whereas KMDA's P/E ratio is 22.68. In terms of profitability, EVO's ROE is -0.27%, compared to KMDA's ROE of +0.08%. Regarding short-term risk, EVO is less volatile compared to KMDA. This indicates lower risk in terms of short-term price fluctuations for EVO.Check KMDA's competition here
Alpha Teknova, Inc. (NASDAQ: TKNO)
EVO vs TKNO Comparison September 2026
Evotec SE (NASDAQ: EVO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EVO stands at 564.8M. In comparison, TKNO has a market cap of 493.2M. Regarding current trading prices, EVO is priced at $1.59 on the NASDAQ, while TKNO trades at $9.20.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EVO currently has a P/E ratio of -2.25, whereas TKNO's P/E ratio is -29.68. In terms of profitability, EVO's ROE is -0.27%, compared to TKNO's ROE of -0.25%. Regarding short-term risk, EVO is less volatile compared to TKNO. This indicates lower risk in terms of short-term price fluctuations for EVO.Check TKNO's competition here
Tilray Brands, Inc. (NASDAQ: TLRY)
EVO vs TLRY Comparison September 2026
Evotec SE (NASDAQ: EVO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EVO stands at 564.8M. In comparison, TLRY has a market cap of 449.6M. Regarding current trading prices, EVO is priced at $1.59 on the NASDAQ, while TLRY trades at $4.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EVO currently has a P/E ratio of -2.25, whereas TLRY's P/E ratio is -3.71. In terms of profitability, EVO's ROE is -0.27%, compared to TLRY's ROE of -0.08%. Regarding short-term risk, EVO is less volatile compared to TLRY. This indicates lower risk in terms of short-term price fluctuations for EVO.Check TLRY's competition here
Canopy Growth Corporation (NASDAQ: CGC)
EVO vs CGC Comparison September 2026
Evotec SE (NASDAQ: EVO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EVO stands at 564.8M. In comparison, CGC has a market cap of 390.7M. Regarding current trading prices, EVO is priced at $1.59 on the NASDAQ, while CGC trades at $0.93.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EVO currently has a P/E ratio of -2.25, whereas CGC's P/E ratio is -2.07. In terms of profitability, EVO's ROE is -0.27%, compared to CGC's ROE of -0.33%. Regarding short-term risk, EVO is less volatile compared to CGC. This indicates lower risk in terms of short-term price fluctuations for EVO.Check CGC's competition here
Emergent BioSolutions Inc. (NYSE: EBS)
EVO vs EBS Comparison September 2026
Evotec SE (NASDAQ: EVO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EVO stands at 564.8M. In comparison, EBS has a market cap of 354M. Regarding current trading prices, EVO is priced at $1.59 on the NASDAQ, while EBS trades at $6.86.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EVO currently has a P/E ratio of -2.25, whereas EBS's P/E ratio is 4.76. In terms of profitability, EVO's ROE is -0.27%, compared to EBS's ROE of -0.36%. Regarding short-term risk, EVO is less volatile compared to EBS. This indicates lower risk in terms of short-term price fluctuations for EVO.Check EBS's competition here
Alimera Sciences, Inc. (NASDAQ: ALIM)
EVO vs ALIM Comparison September 2026
Evotec SE (NASDAQ: EVO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EVO stands at 564.8M. In comparison, ALIM has a market cap of 301.3M. Regarding current trading prices, EVO is priced at $1.59 on the NASDAQ, while ALIM trades at $5.54.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EVO currently has a P/E ratio of -2.25, whereas ALIM's P/E ratio is 5.28. In terms of profitability, EVO's ROE is -0.27%, compared to ALIM's ROE of -1.59%. Regarding short-term risk, EVO is more volatile compared to ALIM. This indicates higher risk in terms of short-term price fluctuations for EVO.Check ALIM's competition here
Landec Corporation (NASDAQ: LNDC)
EVO vs LNDC Comparison September 2026
Evotec SE (NASDAQ: EVO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EVO stands at 564.8M. In comparison, LNDC has a market cap of 263.6M. Regarding current trading prices, EVO is priced at $1.59 on the NASDAQ, while LNDC trades at $8.76.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EVO currently has a P/E ratio of -2.25, whereas LNDC's P/E ratio is -4.04. In terms of profitability, EVO's ROE is -0.27%, compared to LNDC's ROE of +6.44%. Regarding short-term risk, EVO is less volatile compared to LNDC. This indicates lower risk in terms of short-term price fluctuations for EVO.Check LNDC's competition here
Aurora Cannabis Inc. (NASDAQ: ACB)
EVO vs ACB Comparison September 2026
Evotec SE (NASDAQ: EVO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EVO stands at 564.8M. In comparison, ACB has a market cap of 253.3M. Regarding current trading prices, EVO is priced at $1.59 on the NASDAQ, while ACB trades at $4.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EVO currently has a P/E ratio of -2.25, whereas ACB's P/E ratio is -2.95. In terms of profitability, EVO's ROE is -0.27%, compared to ACB's ROE of -0.21%. Regarding short-term risk, EVO is less volatile compared to ACB. This indicates lower risk in terms of short-term price fluctuations for EVO.Check ACB's competition here
SIGA Technologies, Inc. (NASDAQ: SIGA)
EVO vs SIGA Comparison September 2026
Evotec SE (NASDAQ: EVO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EVO stands at 564.8M. In comparison, SIGA has a market cap of 248.2M. Regarding current trading prices, EVO is priced at $1.59 on the NASDAQ, while SIGA trades at $3.46.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EVO currently has a P/E ratio of -2.25, whereas SIGA's P/E ratio is 12.81. In terms of profitability, EVO's ROE is -0.27%, compared to SIGA's ROE of -0.02%. Regarding short-term risk, EVO is less volatile compared to SIGA. This indicates lower risk in terms of short-term price fluctuations for EVO.Check SIGA's competition here
Lifecore Biomedical, Inc. (NASDAQ: LFCR)
EVO vs LFCR Comparison September 2026
Evotec SE (NASDAQ: EVO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EVO stands at 564.8M. In comparison, LFCR has a market cap of 244.6M. Regarding current trading prices, EVO is priced at $1.59 on the NASDAQ, while LFCR trades at $6.52.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EVO currently has a P/E ratio of -2.25, whereas LFCR's P/E ratio is -5.13. In terms of profitability, EVO's ROE is -0.27%, compared to LFCR's ROE of -3.77%. Regarding short-term risk, EVO is less volatile compared to LFCR. This indicates lower risk in terms of short-term price fluctuations for EVO.Check LFCR's competition here
Shineco, Inc. (NASDAQ: TYHT)
EVO vs TYHT Comparison September 2026
Evotec SE (NASDAQ: EVO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EVO stands at 564.8M. In comparison, TYHT has a market cap of 229.2M. Regarding current trading prices, EVO is priced at $1.59 on the NASDAQ, while TYHT trades at $11.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EVO currently has a P/E ratio of -2.25, whereas TYHT's P/E ratio is -1.61. In terms of profitability, EVO's ROE is -0.27%, compared to TYHT's ROE of -0.57%. Regarding short-term risk, EVO is less volatile compared to TYHT. This indicates lower risk in terms of short-term price fluctuations for EVO.Check TYHT's competition here
Cardiol Therapeutics Inc. (NASDAQ: CRDL)
EVO vs CRDL Comparison September 2026
Evotec SE (NASDAQ: EVO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EVO stands at 564.8M. In comparison, CRDL has a market cap of 194.8M. Regarding current trading prices, EVO is priced at $1.59 on the NASDAQ, while CRDL trades at $1.69.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EVO currently has a P/E ratio of -2.25, whereas CRDL's P/E ratio is -6.73. In terms of profitability, EVO's ROE is -0.27%, compared to CRDL's ROE of -1.94%. Regarding short-term risk, EVO is less volatile compared to CRDL. This indicates lower risk in terms of short-term price fluctuations for EVO.Check CRDL's competition here
Organogenesis Holdings Inc. (NASDAQ: ORGO)
EVO vs ORGO Comparison September 2026
Evotec SE (NASDAQ: EVO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EVO stands at 564.8M. In comparison, ORGO has a market cap of 177.6M. Regarding current trading prices, EVO is priced at $1.59 on the NASDAQ, while ORGO trades at $1.38.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EVO currently has a P/E ratio of -2.25, whereas ORGO's P/E ratio is 46.00. In terms of profitability, EVO's ROE is -0.27%, compared to ORGO's ROE of -0.24%. Regarding short-term risk, EVO is less volatile compared to ORGO. This indicates lower risk in terms of short-term price fluctuations for EVO.Check ORGO's competition here
Recro Pharma, Inc. (NASDAQ: REPH)
EVO vs REPH Comparison September 2026
Evotec SE (NASDAQ: EVO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EVO stands at 564.8M. In comparison, REPH has a market cap of 177.4M. Regarding current trading prices, EVO is priced at $1.59 on the NASDAQ, while REPH trades at $2.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EVO currently has a P/E ratio of -2.25, whereas REPH's P/E ratio is -8.04. In terms of profitability, EVO's ROE is -0.27%, compared to REPH's ROE of -0.22%. Regarding short-term risk, EVO is less volatile compared to REPH. This indicates lower risk in terms of short-term price fluctuations for EVO.Check REPH's competition here
Journey Medical Corporation (NASDAQ: DERM)
EVO vs DERM Comparison September 2026
Evotec SE (NASDAQ: EVO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EVO stands at 564.8M. In comparison, DERM has a market cap of 177M. Regarding current trading prices, EVO is priced at $1.59 on the NASDAQ, while DERM trades at $6.43.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EVO currently has a P/E ratio of -2.25, whereas DERM's P/E ratio is -29.23. In terms of profitability, EVO's ROE is -0.27%, compared to DERM's ROE of -0.20%. Regarding short-term risk, EVO is less volatile compared to DERM. This indicates lower risk in terms of short-term price fluctuations for EVO.Check DERM's competition here
Theratechnologies Inc. (NASDAQ: THTX)
EVO vs THTX Comparison September 2026
Evotec SE (NASDAQ: EVO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EVO stands at 564.8M. In comparison, THTX has a market cap of 155.9M. Regarding current trading prices, EVO is priced at $1.59 on the NASDAQ, while THTX trades at $3.39.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EVO currently has a P/E ratio of -2.25, whereas THTX's P/E ratio is -28.83. In terms of profitability, EVO's ROE is -0.27%, compared to THTX's ROE of +0.36%. Regarding short-term risk, EVO is more volatile compared to THTX. This indicates higher risk in terms of short-term price fluctuations for EVO.Check THTX's competition here
Organigram Global Inc. (NASDAQ: OGI)
EVO vs OGI Comparison September 2026
Evotec SE (NASDAQ: EVO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EVO stands at 564.8M. In comparison, OGI has a market cap of 152.7M. Regarding current trading prices, EVO is priced at $1.59 on the NASDAQ, while OGI trades at $1.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EVO currently has a P/E ratio of -2.25, whereas OGI's P/E ratio is 2.44. In terms of profitability, EVO's ROE is -0.27%, compared to OGI's ROE of +0.21%. Regarding short-term risk, EVO is less volatile compared to OGI. This indicates lower risk in terms of short-term price fluctuations for EVO.Check OGI's competition here
Assertio Holdings, Inc. (NASDAQ: ASRT)
EVO vs ASRT Comparison September 2026
Evotec SE (NASDAQ: EVO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EVO stands at 564.8M. In comparison, ASRT has a market cap of 151.9M. Regarding current trading prices, EVO is priced at $1.59 on the NASDAQ, while ASRT trades at $23.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EVO currently has a P/E ratio of -2.25, whereas ASRT's P/E ratio is -7.10. In terms of profitability, EVO's ROE is -0.27%, compared to ASRT's ROE of -0.39%. Regarding short-term risk, EVO is more volatile compared to ASRT. This indicates higher risk in terms of short-term price fluctuations for EVO.Check ASRT's competition here
Societal CDMO, Inc. (NASDAQ: SCTL)
EVO vs SCTL Comparison September 2026
Evotec SE (NASDAQ: EVO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EVO stands at 564.8M. In comparison, SCTL has a market cap of 116.1M. Regarding current trading prices, EVO is priced at $1.59 on the NASDAQ, while SCTL trades at $1.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EVO currently has a P/E ratio of -2.25, whereas SCTL's P/E ratio is -7.86. In terms of profitability, EVO's ROE is -0.27%, compared to SCTL's ROE of -0.22%. Regarding short-term risk, EVO is more volatile compared to SCTL. This indicates higher risk in terms of short-term price fluctuations for EVO.Check SCTL's competition here
Cumberland Pharmaceuticals Inc. (NASDAQ: CPIX)
EVO vs CPIX Comparison September 2026
Evotec SE (NASDAQ: EVO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EVO stands at 564.8M. In comparison, CPIX has a market cap of 115.7M. Regarding current trading prices, EVO is priced at $1.59 on the NASDAQ, while CPIX trades at $7.72.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EVO currently has a P/E ratio of -2.25, whereas CPIX's P/E ratio is -19.30. In terms of profitability, EVO's ROE is -0.27%, compared to CPIX's ROE of -0.47%. Regarding short-term risk, EVO is less volatile compared to CPIX. This indicates lower risk in terms of short-term price fluctuations for EVO.Check CPIX's competition here
Procaps Group S.A. (NASDAQ: PROC)
EVO vs PROC Comparison September 2026
Evotec SE (NASDAQ: EVO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EVO stands at 564.8M. In comparison, PROC has a market cap of 102.1M. Regarding current trading prices, EVO is priced at $1.59 on the NASDAQ, while PROC trades at $1.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EVO currently has a P/E ratio of -2.25, whereas PROC's P/E ratio is 1.53. In terms of profitability, EVO's ROE is -0.27%, compared to PROC's ROE of -2.22%. Regarding short-term risk, EVO is more volatile compared to PROC. This indicates higher risk in terms of short-term price fluctuations for EVO.Check PROC's competition here
OptiNose, Inc. (NASDAQ: OPTN)
EVO vs OPTN Comparison September 2026
Evotec SE (NASDAQ: EVO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EVO stands at 564.8M. In comparison, OPTN has a market cap of 97.2M. Regarding current trading prices, EVO is priced at $1.59 on the NASDAQ, while OPTN trades at $9.60.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EVO currently has a P/E ratio of -2.25, whereas OPTN's P/E ratio is -4.42. In terms of profitability, EVO's ROE is -0.27%, compared to OPTN's ROE of +0.34%. Regarding short-term risk, EVO is more volatile compared to OPTN. This indicates higher risk in terms of short-term price fluctuations for EVO.Check OPTN's competition here
Zomedica Corp. (AMEX: ZOM)
EVO vs ZOM Comparison September 2026
Evotec SE (NASDAQ: EVO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EVO stands at 564.8M. In comparison, ZOM has a market cap of 95.3M. Regarding current trading prices, EVO is priced at $1.59 on the NASDAQ, while ZOM trades at $0.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EVO currently has a P/E ratio of -2.25, whereas ZOM's P/E ratio is -1.62. In terms of profitability, EVO's ROE is -0.27%, compared to ZOM's ROE of -0.17%. Regarding short-term risk, EVO is less volatile compared to ZOM. This indicates lower risk in terms of short-term price fluctuations for EVO.Check ZOM's competition here
Upexi, Inc. (NASDAQ: GRVI)
EVO vs GRVI Comparison September 2026
Evotec SE (NASDAQ: EVO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EVO stands at 564.8M. In comparison, GRVI has a market cap of 88.9M. Regarding current trading prices, EVO is priced at $1.59 on the NASDAQ, while GRVI trades at $4.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EVO currently has a P/E ratio of -2.25, whereas GRVI's P/E ratio is 26.05. In terms of profitability, EVO's ROE is -0.27%, compared to GRVI's ROE of -4.51%. Regarding short-term risk, EVO is less volatile compared to GRVI. This indicates lower risk in terms of short-term price fluctuations for EVO.Check GRVI's competition here
BGM Group Ltd. (NASDAQ: BGM)
EVO vs BGM Comparison September 2026
Evotec SE (NASDAQ: EVO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EVO stands at 564.8M. In comparison, BGM has a market cap of 88.8M. Regarding current trading prices, EVO is priced at $1.59 on the NASDAQ, while BGM trades at $0.24.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EVO currently has a P/E ratio of -2.25, whereas BGM's P/E ratio is -1.46. In terms of profitability, EVO's ROE is -0.27%, compared to BGM's ROE of -0.05%. Regarding short-term risk, EVO is less volatile compared to BGM. This indicates lower risk in terms of short-term price fluctuations for EVO.Check BGM's competition here
Zynerba Pharmaceuticals, Inc. (NASDAQ: ZYNE)
EVO vs ZYNE Comparison September 2026
Evotec SE (NASDAQ: EVO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EVO stands at 564.8M. In comparison, ZYNE has a market cap of 70.1M. Regarding current trading prices, EVO is priced at $1.59 on the NASDAQ, while ZYNE trades at $1.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EVO currently has a P/E ratio of -2.25, whereas ZYNE's P/E ratio is -1.65. In terms of profitability, EVO's ROE is -0.27%, compared to ZYNE's ROE of -0.59%. Regarding short-term risk, EVO is less volatile compared to ZYNE. This indicates lower risk in terms of short-term price fluctuations for EVO.Check ZYNE's competition here
Silver Spike Investment Corp. (NASDAQ: SSIC)
EVO vs SSIC Comparison September 2026
Evotec SE (NASDAQ: EVO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EVO stands at 564.8M. In comparison, SSIC has a market cap of 66.7M. Regarding current trading prices, EVO is priced at $1.59 on the NASDAQ, while SSIC trades at $10.74.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EVO currently has a P/E ratio of -2.25, whereas SSIC's P/E ratio is 11.93. In terms of profitability, EVO's ROE is -0.27%, compared to SSIC's ROE of +0.00%. Regarding short-term risk, EVO is less volatile compared to SSIC. This indicates lower risk in terms of short-term price fluctuations for EVO.Check SSIC's competition here
Talphera, Inc. (NASDAQ: TLPH)
EVO vs TLPH Comparison September 2026
Evotec SE (NASDAQ: EVO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EVO stands at 564.8M. In comparison, TLPH has a market cap of 61.8M. Regarding current trading prices, EVO is priced at $1.59 on the NASDAQ, while TLPH trades at $1.19.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EVO currently has a P/E ratio of -2.25, whereas TLPH's P/E ratio is -3.84. In terms of profitability, EVO's ROE is -0.27%, compared to TLPH's ROE of -0.87%. Regarding short-term risk, EVO is less volatile compared to TLPH. This indicates lower risk in terms of short-term price fluctuations for EVO.Check TLPH's competition here
Zhengye Biotechnology Holding Limited (NASDAQ: ZYBT)
EVO vs ZYBT Comparison September 2026
Evotec SE (NASDAQ: EVO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EVO stands at 564.8M. In comparison, ZYBT has a market cap of 61.6M. Regarding current trading prices, EVO is priced at $1.59 on the NASDAQ, while ZYBT trades at $1.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EVO currently has a P/E ratio of -2.25, whereas ZYBT's P/E ratio is -6.32. In terms of profitability, EVO's ROE is -0.27%, compared to ZYBT's ROE of -0.27%. Regarding short-term risk, EVO is less volatile compared to ZYBT. This indicates lower risk in terms of short-term price fluctuations for EVO.Check ZYBT's competition here
The Valens Company Inc. (NASDAQ: VLNS)
EVO vs VLNS Comparison September 2026
Evotec SE (NASDAQ: EVO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EVO stands at 564.8M. In comparison, VLNS has a market cap of 61.5M. Regarding current trading prices, EVO is priced at $1.59 on the NASDAQ, while VLNS trades at $0.76.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EVO currently has a P/E ratio of -2.25, whereas VLNS's P/E ratio is -1.03. In terms of profitability, EVO's ROE is -0.27%, compared to VLNS's ROE of N/A. Regarding short-term risk, EVO is less volatile compared to VLNS. This indicates lower risk in terms of short-term price fluctuations for EVO.Check VLNS's competition here
InterCure Ltd. (NASDAQ: INCR)
EVO vs INCR Comparison September 2026
Evotec SE (NASDAQ: EVO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EVO stands at 564.8M. In comparison, INCR has a market cap of 60.7M. Regarding current trading prices, EVO is priced at $1.59 on the NASDAQ, while INCR trades at $5.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EVO currently has a P/E ratio of -2.25, whereas INCR's P/E ratio is -4.92. In terms of profitability, EVO's ROE is -0.27%, compared to INCR's ROE of -0.09%. Regarding short-term risk, EVO is more volatile compared to INCR. This indicates higher risk in terms of short-term price fluctuations for EVO.Check INCR's competition here
DURECT Corporation (NASDAQ: DRRX)
EVO vs DRRX Comparison September 2026
Evotec SE (NASDAQ: EVO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EVO stands at 564.8M. In comparison, DRRX has a market cap of 59.3M. Regarding current trading prices, EVO is priced at $1.59 on the NASDAQ, while DRRX trades at $1.91.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EVO currently has a P/E ratio of -2.25, whereas DRRX's P/E ratio is -4.44. In terms of profitability, EVO's ROE is -0.27%, compared to DRRX's ROE of -1.40%. Regarding short-term risk, EVO is more volatile compared to DRRX. This indicates higher risk in terms of short-term price fluctuations for EVO.Check DRRX's competition here
Jupiter Wellness, Inc. (NASDAQ: JUPW)
EVO vs JUPW Comparison September 2026
Evotec SE (NASDAQ: EVO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EVO stands at 564.8M. In comparison, JUPW has a market cap of 49.3M. Regarding current trading prices, EVO is priced at $1.59 on the NASDAQ, while JUPW trades at $1.52.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EVO currently has a P/E ratio of -2.25, whereas JUPW's P/E ratio is -2.41. In terms of profitability, EVO's ROE is -0.27%, compared to JUPW's ROE of -3.04%. Regarding short-term risk, EVO is less volatile compared to JUPW. This indicates lower risk in terms of short-term price fluctuations for EVO.Check JUPW's competition here
Qilian International Holding Group Limited (NASDAQ: QLI)
EVO vs QLI Comparison September 2026
Evotec SE (NASDAQ: EVO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EVO stands at 564.8M. In comparison, QLI has a market cap of 38.7M. Regarding current trading prices, EVO is priced at $1.59 on the NASDAQ, while QLI trades at $5.41.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EVO currently has a P/E ratio of -2.25, whereas QLI's P/E ratio is -4.92. In terms of profitability, EVO's ROE is -0.27%, compared to QLI's ROE of -0.16%. Regarding short-term risk, EVO is more volatile compared to QLI. This indicates higher risk in terms of short-term price fluctuations for EVO.Check QLI's competition here
Rockwell Medical, Inc. (NASDAQ: RMTI)
EVO vs RMTI Comparison September 2026
Evotec SE (NASDAQ: EVO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EVO stands at 564.8M. In comparison, RMTI has a market cap of 34.1M. Regarding current trading prices, EVO is priced at $1.59 on the NASDAQ, while RMTI trades at $8.63.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EVO currently has a P/E ratio of -2.25, whereas RMTI's P/E ratio is -6.44. In terms of profitability, EVO's ROE is -0.27%, compared to RMTI's ROE of -0.14%. Regarding short-term risk, EVO is less volatile compared to RMTI. This indicates lower risk in terms of short-term price fluctuations for EVO.Check RMTI's competition here
HEXO Corp. (NASDAQ: HEXO)
EVO vs HEXO Comparison September 2026
Evotec SE (NASDAQ: EVO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EVO stands at 564.8M. In comparison, HEXO has a market cap of 31.2M. Regarding current trading prices, EVO is priced at $1.59 on the NASDAQ, while HEXO trades at $0.71.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EVO currently has a P/E ratio of -2.25, whereas HEXO's P/E ratio is -0.26. In terms of profitability, EVO's ROE is -0.27%, compared to HEXO's ROE of -2.06%. Regarding short-term risk, EVO is less volatile compared to HEXO. This indicates lower risk in terms of short-term price fluctuations for EVO.Check HEXO's competition here
China Pharma Holdings, Inc. (AMEX: CPHI)
EVO vs CPHI Comparison September 2026
Evotec SE (NASDAQ: EVO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EVO stands at 564.8M. In comparison, CPHI has a market cap of 29.5M. Regarding current trading prices, EVO is priced at $1.59 on the NASDAQ, while CPHI trades at $0.72.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EVO currently has a P/E ratio of -2.25, whereas CPHI's P/E ratio is -1.69. In terms of profitability, EVO's ROE is -0.27%, compared to CPHI's ROE of -0.17%. Regarding short-term risk, EVO is less volatile compared to CPHI. This indicates lower risk in terms of short-term price fluctuations for EVO.Check CPHI's competition here
TherapeuticsMD, Inc. (NASDAQ: TXMD)
EVO vs TXMD Comparison September 2026
Evotec SE (NASDAQ: EVO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EVO stands at 564.8M. In comparison, TXMD has a market cap of 24.2M. Regarding current trading prices, EVO is priced at $1.59 on the NASDAQ, while TXMD trades at $2.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EVO currently has a P/E ratio of -2.25, whereas TXMD's P/E ratio is 106.47. In terms of profitability, EVO's ROE is -0.27%, compared to TXMD's ROE of -0.01%. Regarding short-term risk, EVO is less volatile compared to TXMD. This indicates lower risk in terms of short-term price fluctuations for EVO.Check TXMD's competition here
Cyclo Therapeutics, Inc. (NASDAQ: CYTH)
EVO vs CYTH Comparison September 2026
Evotec SE (NASDAQ: EVO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EVO stands at 564.8M. In comparison, CYTH has a market cap of 23.6M. Regarding current trading prices, EVO is priced at $1.59 on the NASDAQ, while CYTH trades at $0.72.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EVO currently has a P/E ratio of -2.25, whereas CYTH's P/E ratio is -0.80. In terms of profitability, EVO's ROE is -0.27%, compared to CYTH's ROE of -7.30%. Regarding short-term risk, EVO is more volatile compared to CYTH. This indicates higher risk in terms of short-term price fluctuations for EVO.Check CYTH's competition here
Aytu BioPharma, Inc. (NASDAQ: AYTU)
EVO vs AYTU Comparison September 2026
Evotec SE (NASDAQ: EVO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EVO stands at 564.8M. In comparison, AYTU has a market cap of 23.3M. Regarding current trading prices, EVO is priced at $1.59 on the NASDAQ, while AYTU trades at $2.17.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EVO currently has a P/E ratio of -2.25, whereas AYTU's P/E ratio is -0.47. In terms of profitability, EVO's ROE is -0.27%, compared to AYTU's ROE of -0.53%. Regarding short-term risk, EVO is less volatile compared to AYTU. This indicates lower risk in terms of short-term price fluctuations for EVO.Check AYTU's competition here
Evoke Pharma, Inc. (NASDAQ: EVOK)
EVO vs EVOK Comparison September 2026
Evotec SE (NASDAQ: EVO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EVO stands at 564.8M. In comparison, EVOK has a market cap of 18.9M. Regarding current trading prices, EVO is priced at $1.59 on the NASDAQ, while EVOK trades at $11.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EVO currently has a P/E ratio of -2.25, whereas EVOK's P/E ratio is -7.97. In terms of profitability, EVO's ROE is -0.27%, compared to EVOK's ROE of -0.89%. Regarding short-term risk, EVO is more volatile compared to EVOK. This indicates higher risk in terms of short-term price fluctuations for EVO.Check EVOK's competition here
Optimi Health Corp. (NASDAQ: OPTH)
EVO vs OPTH Comparison September 2026
Evotec SE (NASDAQ: EVO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EVO stands at 564.8M. In comparison, OPTH has a market cap of 15.6M. Regarding current trading prices, EVO is priced at $1.59 on the NASDAQ, while OPTH trades at $4.85.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EVO currently has a P/E ratio of -2.25, whereas OPTH's P/E ratio is -3.37. In terms of profitability, EVO's ROE is -0.27%, compared to OPTH's ROE of -0.90%. Regarding short-term risk, EVO is less volatile compared to OPTH. This indicates lower risk in terms of short-term price fluctuations for EVO.Check OPTH's competition here
AcelRx Pharmaceuticals, Inc. (NASDAQ: ACRX)
EVO vs ACRX Comparison September 2026
Evotec SE (NASDAQ: EVO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EVO stands at 564.8M. In comparison, ACRX has a market cap of 14.6M. Regarding current trading prices, EVO is priced at $1.59 on the NASDAQ, while ACRX trades at $0.86.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EVO currently has a P/E ratio of -2.25, whereas ACRX's P/E ratio is -0.31. In terms of profitability, EVO's ROE is -0.27%, compared to ACRX's ROE of -0.87%. Regarding short-term risk, EVO is less volatile compared to ACRX. This indicates lower risk in terms of short-term price fluctuations for EVO.Check ACRX's competition here
Caring Brands, Inc. (NASDAQ: CABR)
EVO vs CABR Comparison September 2026
Evotec SE (NASDAQ: EVO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EVO stands at 564.8M. In comparison, CABR has a market cap of 11.3M. Regarding current trading prices, EVO is priced at $1.59 on the NASDAQ, while CABR trades at $1.24.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EVO currently has a P/E ratio of -2.25, whereas CABR's P/E ratio is -1.59. In terms of profitability, EVO's ROE is -0.27%, compared to CABR's ROE of -3.86%. Regarding short-term risk, EVO is less volatile compared to CABR. This indicates lower risk in terms of short-term price fluctuations for EVO.Check CABR's competition here
Agile Therapeutics, Inc. (NASDAQ: AGRX)
EVO vs AGRX Comparison September 2026
Evotec SE (NASDAQ: EVO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EVO stands at 564.8M. In comparison, AGRX has a market cap of 10.4M. Regarding current trading prices, EVO is priced at $1.59 on the NASDAQ, while AGRX trades at $1.51.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EVO currently has a P/E ratio of -2.25, whereas AGRX's P/E ratio is -0.89. In terms of profitability, EVO's ROE is -0.27%, compared to AGRX's ROE of +1.32%. Regarding short-term risk, EVO is less volatile compared to AGRX. This indicates lower risk in terms of short-term price fluctuations for EVO.Check AGRX's competition here
Neoleukin Therapeutics, Inc. (NASDAQ: NLTX)
EVO vs NLTX Comparison September 2026
Evotec SE (NASDAQ: EVO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EVO stands at 564.8M. In comparison, NLTX has a market cap of 8.2M. Regarding current trading prices, EVO is priced at $1.59 on the NASDAQ, while NLTX trades at $3.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EVO currently has a P/E ratio of -2.25, whereas NLTX's P/E ratio is -0.28. In terms of profitability, EVO's ROE is -0.27%, compared to NLTX's ROE of -0.45%. Regarding short-term risk, EVO is less volatile compared to NLTX. This indicates lower risk in terms of short-term price fluctuations for EVO.Check NLTX's competition here
Lannett Company, Inc. (NYSE: LCI)
EVO vs LCI Comparison September 2026
Evotec SE (NASDAQ: EVO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EVO stands at 564.8M. In comparison, LCI has a market cap of 7.4M. Regarding current trading prices, EVO is priced at $1.59 on the NASDAQ, while LCI trades at $0.69.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EVO currently has a P/E ratio of -2.25, whereas LCI's P/E ratio is -0.04. In terms of profitability, EVO's ROE is -0.27%, compared to LCI's ROE of +1.66%. Regarding short-term risk, EVO is less volatile compared to LCI. This indicates lower risk in terms of short-term price fluctuations for EVO.Check LCI's competition here
Adamis Pharmaceuticals Corporation (NASDAQ: ADMP)
EVO vs ADMP Comparison September 2026
Evotec SE (NASDAQ: EVO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EVO stands at 564.8M. In comparison, ADMP has a market cap of 7.3M. Regarding current trading prices, EVO is priced at $1.59 on the NASDAQ, while ADMP trades at $0.78.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EVO currently has a P/E ratio of -2.25, whereas ADMP's P/E ratio is -0.08. In terms of profitability, EVO's ROE is -0.27%, compared to ADMP's ROE of -2.09%. Regarding short-term risk, EVO is less volatile compared to ADMP. This indicates lower risk in terms of short-term price fluctuations for EVO.Check ADMP's competition here
Gelteq Limited Ordinary Shares (NASDAQ: GELS)
EVO vs GELS Comparison September 2026
Evotec SE (NASDAQ: EVO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EVO stands at 564.8M. In comparison, GELS has a market cap of 5M. Regarding current trading prices, EVO is priced at $1.59 on the NASDAQ, while GELS trades at $0.55.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EVO currently has a P/E ratio of -2.25, whereas GELS's P/E ratio is -1.09. In terms of profitability, EVO's ROE is -0.27%, compared to GELS's ROE of -0.25%. Regarding short-term risk, EVO is less volatile compared to GELS. This indicates lower risk in terms of short-term price fluctuations for EVO.Check GELS's competition here
cbdMD, Inc. (AMEX: YCBD)
EVO vs YCBD Comparison September 2026
Evotec SE (NASDAQ: EVO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EVO stands at 564.8M. In comparison, YCBD has a market cap of 4.9M. Regarding current trading prices, EVO is priced at $1.59 on the NASDAQ, while YCBD trades at $0.46.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EVO currently has a P/E ratio of -2.25, whereas YCBD's P/E ratio is -1.14. In terms of profitability, EVO's ROE is -0.27%, compared to YCBD's ROE of -0.34%. Regarding short-term risk, EVO is less volatile compared to YCBD. This indicates lower risk in terms of short-term price fluctuations for EVO.Check YCBD's competition here
Mallinckrodt plc (AMEX: MNK)
EVO vs MNK Comparison September 2026
Evotec SE (NASDAQ: EVO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EVO stands at 564.8M. In comparison, MNK has a market cap of 4.5M. Regarding current trading prices, EVO is priced at $1.59 on the NASDAQ, while MNK trades at $0.34.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EVO currently has a P/E ratio of -2.25, whereas MNK's P/E ratio is -0.44. In terms of profitability, EVO's ROE is -0.27%, compared to MNK's ROE of -0.36%. Regarding short-term risk, EVO is less volatile compared to MNK. This indicates lower risk in terms of short-term price fluctuations for EVO.Check MNK's competition here
Flora Growth Corp. (NASDAQ: FLGC)
EVO vs FLGC Comparison September 2026
Evotec SE (NASDAQ: EVO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EVO stands at 564.8M. In comparison, FLGC has a market cap of 4.2M. Regarding current trading prices, EVO is priced at $1.59 on the NASDAQ, while FLGC trades at $7.79.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EVO currently has a P/E ratio of -2.25, whereas FLGC's P/E ratio is -0.19. In terms of profitability, EVO's ROE is -0.27%, compared to FLGC's ROE of -3.03%. Regarding short-term risk, EVO is less volatile compared to FLGC. This indicates lower risk in terms of short-term price fluctuations for EVO.Check FLGC's competition here
Universe Pharmaceuticals Inc. (NASDAQ: UPC)
EVO vs UPC Comparison September 2026
Evotec SE (NASDAQ: EVO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EVO stands at 564.8M. In comparison, UPC has a market cap of 3.1M. Regarding current trading prices, EVO is priced at $1.59 on the NASDAQ, while UPC trades at $4.80.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EVO currently has a P/E ratio of -2.25, whereas UPC's P/E ratio is -0.61. In terms of profitability, EVO's ROE is -0.27%, compared to UPC's ROE of -0.03%. Regarding short-term risk, EVO is less volatile compared to UPC. This indicates lower risk in terms of short-term price fluctuations for EVO.Check UPC's competition here
PLx Pharma Inc. (NASDAQ: PLXP)
EVO vs PLXP Comparison September 2026
Evotec SE (NASDAQ: EVO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EVO stands at 564.8M. In comparison, PLXP has a market cap of 2.5M. Regarding current trading prices, EVO is priced at $1.59 on the NASDAQ, while PLXP trades at $0.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EVO currently has a P/E ratio of -2.25, whereas PLXP's P/E ratio is -0.22. In terms of profitability, EVO's ROE is -0.27%, compared to PLXP's ROE of -1.66%. Regarding short-term risk, EVO is less volatile compared to PLXP. This indicates lower risk in terms of short-term price fluctuations for EVO.Check PLXP's competition here
InMed Pharmaceuticals Inc. (NASDAQ: INM)
EVO vs INM Comparison September 2026
Evotec SE (NASDAQ: EVO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EVO stands at 564.8M. In comparison, INM has a market cap of 2.5M. Regarding current trading prices, EVO is priced at $1.59 on the NASDAQ, while INM trades at $1.36.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EVO currently has a P/E ratio of -2.25, whereas INM's P/E ratio is -0.25. In terms of profitability, EVO's ROE is -0.27%, compared to INM's ROE of -1.35%. Regarding short-term risk, EVO is more volatile compared to INM. This indicates higher risk in terms of short-term price fluctuations for EVO.Check INM's competition here
Shuttle Pharmaceuticals Holdings, Inc. (NASDAQ: SHPH)
EVO vs SHPH Comparison September 2026
Evotec SE (NASDAQ: EVO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EVO stands at 564.8M. In comparison, SHPH has a market cap of 2.4M. Regarding current trading prices, EVO is priced at $1.59 on the NASDAQ, while SHPH trades at $4.11.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EVO currently has a P/E ratio of -2.25, whereas SHPH's P/E ratio is -0.19. In terms of profitability, EVO's ROE is -0.27%, compared to SHPH's ROE of -1.57%. Regarding short-term risk, EVO is less volatile compared to SHPH. This indicates lower risk in terms of short-term price fluctuations for EVO.Check SHPH's competition here
Athenex, Inc. (NASDAQ: ATNX)
EVO vs ATNX Comparison September 2026
Evotec SE (NASDAQ: EVO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EVO stands at 564.8M. In comparison, ATNX has a market cap of 2.3M. Regarding current trading prices, EVO is priced at $1.59 on the NASDAQ, while ATNX trades at $0.20.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EVO currently has a P/E ratio of -2.25, whereas ATNX's P/E ratio is -0.02. In terms of profitability, EVO's ROE is -0.27%, compared to ATNX's ROE of +0.22%. Regarding short-term risk, EVO is more volatile compared to ATNX. This indicates higher risk in terms of short-term price fluctuations for EVO.Check ATNX's competition here
Sonoma Pharmaceuticals, Inc. (NASDAQ: SNOA)
EVO vs SNOA Comparison September 2026
Evotec SE (NASDAQ: EVO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EVO stands at 564.8M. In comparison, SNOA has a market cap of 2.1M. Regarding current trading prices, EVO is priced at $1.59 on the NASDAQ, while SNOA trades at $1.26.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EVO currently has a P/E ratio of -2.25, whereas SNOA's P/E ratio is -1.14. In terms of profitability, EVO's ROE is -0.27%, compared to SNOA's ROE of -0.54%. Regarding short-term risk, EVO is less volatile compared to SNOA. This indicates lower risk in terms of short-term price fluctuations for EVO.Check SNOA's competition here
Procaps Group, S.A. (NASDAQ: PROCW)
EVO vs PROCW Comparison September 2026
Evotec SE (NASDAQ: EVO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EVO stands at 564.8M. In comparison, PROCW has a market cap of 2M. Regarding current trading prices, EVO is priced at $1.59 on the NASDAQ, while PROCW trades at $0.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EVO currently has a P/E ratio of -2.25, whereas PROCW's P/E ratio is N/A. In terms of profitability, EVO's ROE is -0.27%, compared to PROCW's ROE of -2.22%. Regarding short-term risk, EVO is more volatile compared to PROCW. This indicates higher risk in terms of short-term price fluctuations for EVO.Check PROCW's competition here